Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation
暂无分享,去创建一个
A. d’Arminio Monforte | A. Antinori | P. Lorenzini | A. De Luca | G. Marchetti | S. Lo Caputo | F. Castelli | A. di Biagio | G. Lapadula | S. Rusconi | S. Cicalini | G. Gustinetti
[1] M. Fox,et al. Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa , 2017, AIDS patient care and STDs.
[2] D. Klein,et al. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care , 2016, Journal of acquired immune deficiency syndromes.
[3] M. Egger,et al. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population , 2016, Current opinion in HIV and AIDS.
[4] J. Amin,et al. Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. , 2016, The lancet. HIV.
[5] S. Candrilli,et al. Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States , 2016, The Annals of pharmacotherapy.
[6] J. Hardin,et al. Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks. , 2016, The American journal of managed care.
[7] A. Mocroft,et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration , 2016, BMC Medicine.
[8] M. Youle,et al. Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study , 2016, BMC Infectious Diseases.
[9] A. d’Arminio Monforte,et al. Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy , 2016, Journal of acquired immune deficiency syndromes.
[10] Jan Albert,et al. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] D. Kent,et al. Myocardial Infarction, Stroke, and Mortality in cART-Treated HIV Patients on Statins. , 2015, AIDS patient care and STDs.
[12] L. Manzoli,et al. Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: sensitivity and specificity of current guidelines on bone mineral density management. , 2015, AIDS patient care and STDs.
[13] A. Antinori,et al. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort , 2014, Journal of the International AIDS Society.
[14] K. White,et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inf , 2014, The Lancet. Infectious diseases.
[15] K. White,et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b , 2014, The Lancet. Infectious diseases.
[16] D. Ward,et al. Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data , 2014, HIV clinical trials.
[17] L. Sticchi,et al. Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy? , 2014, Recent patents on anti-infective drug discovery.
[18] J. Olalla,et al. Durability of the First Antiretroviral Treatment Regimen and Reasons for Change in Patients With HIV Infection , 2014, HIV clinical trials.
[19] B. Gazzard,et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants , 2014, AIDS.
[20] J. Nachega,et al. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] James J. Goedert,et al. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.
[22] M. Di Nicola,et al. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy , 2013, Journal of medical virology.
[23] I. Olkin,et al. Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review , 2013, PloS one.
[24] Richard D Moore,et al. Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study. , 2013, AIDS research and human retroviruses.
[25] Jianyun Wu,et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta‐analysis , 2012, HIV medicine.
[26] P. Di Carlo,et al. Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected mediterranean subjects , 2012, BMC Infectious Diseases.
[27] L. Calza. Renal Toxicity Associated With Antiretroviral Therapy , 2012, HIV clinical trials.
[28] A. d’Arminio Monforte,et al. The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. , 2012, The new microbiologica.
[29] James D. Scott,et al. Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel , 2012, Annals of Internal Medicine.
[30] P. Tebas,et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents , 2012, AIDS.
[31] A. Westfall,et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] P. Sax,et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. , 2011, The Journal of infectious diseases.
[33] A. Mocroft,et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients , 2010, AIDS.
[34] D. Cooper,et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials , 2010, The Lancet.
[35] D. Ward,et al. Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients , 2009, Journal of acquired immune deficiency syndromes.
[36] D. Podzamczer,et al. Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study , 2009, Journal of acquired immune deficiency syndromes.
[37] B G Gazzard,et al. Switching from twice‐daily abacavir and lamivudine to the once‐daily fixed‐dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy , 2008, HIV medicine.
[38] Lynne Peeples,et al. Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.
[39] M. Witt,et al. Randomization to Once-Daily Stavudine Extended Release/Lamivudine/Efavirenz Versus a More Frequent Regimen Improves Adherence While Maintaining Viral Suppression , 2008, HIV clinical trials.
[40] O. Kirk,et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.
[41] J. Parienti,et al. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study , 2007, AIDS.
[42] J. Sterne,et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies , 2007, AIDS.
[43] Richard D Moore,et al. An Improvement in Virologic Response to Highly Active Antiretroviral Therapy in Clinical Practice From 1996 Through 2002 , 2005, Journal of acquired immune deficiency syndromes.
[44] B. Gazzard,et al. Better maintained adherence on switching from twice‐daily to once‐daily therapy for HIV: a 24‐week randomized trial of treatment simplification using stavudine prolonged‐release capsules , 2005, HIV medicine.
[45] J. Tolson,et al. Perspectives on Adherence and Simplicity for HIV-Infected Patients on Antiretroviral Therapy: Self-Report of the Relative Importance of Multiple Attributes of Highly Active Antiretroviral Therapy (HAART) Regimens in Predicting Adherence , 2004, Journal of acquired immune deficiency syndromes.
[46] P. Narciso,et al. Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. , 2003, AIDS.
[47] F. Maggiolo,et al. Simpler Regimens May Enhance Adherence to Antiretrovirals in HIV-Infected Patients , 2002, HIV clinical trials.
[48] F. Brun-Vézinet,et al. Adherence to Antiretroviral Therapy and Outcomes in HIV-Infected Patients Enrolled in An Induction/Maintenance Randomized Trial , 2001, Antiviral therapy.
[49] M. Moroni,et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.
[50] C. Sabin,et al. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. , 2014, The Journal of infection.
[51] D. Francisci,et al. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. , 2013, The Journal of antimicrobial chemotherapy.
[52] F. Marcos Sánchez,et al. [Duration of highly active antiretroviral therapy regimens]. , 2007, Anales de medicina interna.